Purpose: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. Methods: Retrospective cohort study of 566 eyes in 566 patients with centreinvolved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region. Data were retrieved from a database and patient records between January 2011 and March 2016 and analysed using mixed-model statistics. Results: At the conclusion of follow-up, 24.6% were in active ranibizumab followup, 25.4% had switched to other intravitreal pharmacotherapy, 31.6% had been discontinued because of disease stability, 13.8% had been lost to follow-up, 1.4% had been discontinued because of low visual acuity (VA), and 3.2% had died. At baseline, mean best-corrected visual acuity (BCVA) and mean central subfield thickness (CST) were 64.9 (AE15.0) letters and 400.2 (AE120.3) lm. Mean change in BCVA and mean change in CST from baseline to 3, 12, 24, 36 and 48 months of follow-up were +3.9, +3.5, +2.7, +1.8, +2.3 letters and À97.4, À102.6, À106.9, À105.9, À131.6 lm, respectively. Mean number of injections was 6.1 in year 1 and 1.8 in year 4. In 93 patients, drug switching to aflibercept showed no difference between the two drugs on BCVA or CST. In 79 patients, CST decreased <10% compared to baseline during the first year. Conclusion: In a single-centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national guidelines were followed for up to 4 years. Best-corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.
Introduction
Diabetic macular oedema (DME) is one of the leading causes of vision loss in working-age people, with an estimated global prevalence of 21 million individuals (Yau et al. 2012 ). The beneficial effect of intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors, in improvement of visual acuity (VA) and reduction in retinal thickness, in eyes with centreinvolved DME compared to macular photocoagulation has been documented in multiple controlled clinical trials (Nguyen et al. 2009 (Nguyen et al. , 2012 Diabetic Retinopathy Clinical Research et al. 2010 Massin et al. 2010; Michaelides et al. 2010; Elman et al. 2011 Elman et al. , 2015 Mitchell et al. 2011; Brown et al. 2013; Lang et al. 2013; Korobelnik et al. 2014; Schmidt-Erfurth et al. 2014; Ishibashi et al. 2015; Pearce et al. 2015; Wells et al. 2015; Prunte et al. 2016) . One-year results showed that 20-80% of patients have achieved a gain in best-corrected visual acuity (BCVA) of 10 or more letters improvement and~10-70% have achieved a gain of 15 or more letters (Clinical Diabetic Retinopathy Research Network et al. 2010; Massin et al. 2010; Michaelides et al. 2010; Mitchell et al. 2011; Nguyen et al. 2012; Korobelnik et al. 2014; Ishibashi et al. 2015; Pearce et al. 2015; Wells et al. 2015; Prunte et al. 2016) . Initial studies of ranibizumab (Lucentis, Genentech, CA, USA) in patients with DME used a median of 34 injections in 3 years (Nguyen et al. 2012; Brown et al. 2013) , and vision gains achieved at year 3 were maintained through year 4 with a reduction in treatment (Boyer et al. 2015) . Protocol I conducted by Diabetic Retinopathy Clinical Research network (DRCR.net), evaluating ranibizumab alone or in combination with macular photocoagulation (prompt/ deferred) for DME compared to macular photocoagulation alone, showed that the initial BCVA improvements observed at year 1 were maintained up to 5 years, with the median number of injections decreasing from nine in the first year to 0 in the 5th year (Clinical Diabetic Retinopathy Research Network et al. 2010 Elman et al. 2011 Elman et al. , 2015 . The 36-month RESTORE extension study, a 2-year open-label study with individualized ranibizumab treatment guided by BCVA and investigator-evaluated disease progression criteria, showed similar results, a maintained vision through 3 years with decreasing number of injections . Aflibercept (Eylea, Regeneron Pharmaceuticals, Tarrytown, NY, USA), a new intravitreal VEGF-inhibitor for DME given every 4 or 8 weeks after a loading dose of five injections, showed superior results compared to macular photocoagulation at years 1, 2 and 3 (Korobelnik et al. 2014; Brown et al. 2015; Heier et al. 2016) , and these results were maintained through year 4 with a reduction in treatment (Wykoff et al. 2017) . One-year results in a comparison between aflibercept and ranibizumab showed that in worse levels of baseline VA aflibercept was more effective at improving vision than ranibizumab, no difference was found in patients with mild visual loss and the superiority of aflibercept over ranibizumab was not found at 2 years (Wells et al. 2015 (Wells et al. , 2016 . These results are from selected study populations only including patients with VA below 78 early treatment diabetic retinopathy study (ETDRS) letters, and the most favourable outcomes are achieved with monthly or near-monthly injections given in the first year. Due to the economic aspects of the intense treatment regimen, the Danish national guidelines for treatment recommend fewer injections and a pro re nata (PRN) regimen (RADS 2017) .
In the following, we present an analysis of DME outcomes in a reallife single-centre clinical setting where the Danish national guidelines were followed and intravitreal VEGF inhibition was the main intervention and where treatment included patients with baseline BCVA of 20 ETDRS letters or better. This work will focus on these five questions: (i) What are the longterm outcomes of anti-VEGF treatment in a large real-life single-centre patient population and what are the outcomes in a subpopulation with baseline VA ≥77 ETDRS letters? (ii) What are the patterns of discontinuation? (iii) What is the effect of drug switching from ranibizumab to aflibercept? In addition, it is unclear (iv) what the long-term correlation is between VA and retinal thickness? And (v) what is the proportion of nonimprovers in a nonselected group of patients?
Patients and Methods
This retrospective observational study included all eligible patients who began intravitreal ranibizumab treatment for DME between 1 January 2011 and 31 December 2013 at the Rigshospitalet, Denmark, under a universal coverage public healthcare plan. Data collection closed on 31 March 2016, and thus, there is variation in the duration of follow-up. The primary referral population was the 1.6 million inhabitants of the Greater Copenhagen region. Data were retrieved from a database and patient records.
Inclusion criteria were first ranibizumab injected eye with centre-involved DME, age 18 years or older, type 1 or type 2 diabetes mellitus, BCVA 0.05 or better, and central subfield thickness (CST) ≥250 lm on spectral-domain optical coherence tomography (Topcon 3D OCT, Topcon, Tokyo, Japan).
Exclusion criteria were prior intravitreal anti-VEGF treatment in the study eye, concurrent retinal disease other than diabetic retinopathy (DR) at baseline such as age-related macular degeneration or retinal vein occlusion, having received fewer than two intravitreal injections 3 months after baseline, missing data at baseline and missing data at month 3 or month 6 for CST or BCVA. No exclusions were made for vitreomacular interface abnormalities, prior vitrectomy, and prior macular or panretinal photocoagulation (PRP).
Injection of intravitreal ranibizumab for DME was prescribed for 944 eyes in 690 patients during the period of inclusion. Of these, 346 patients (50.2%) were treated in only one eye during the study. The number of excluded patients was 6 for prior anti-VEGF injections, 26 for fewer than two injections within 3 months of baseline, 34 for missing data, 21 for concurrent retinal disease, three for baseline BCVA <0.05 and 34 for CST <250 lm. Inclusion of second-injected eyes in patients whose first-injected eye did not fulfil the inclusion criteria was made in 23 cases. After exclusions, the study included 566 patients with all DR severity levels.
Treatment protocol
The Danish national guidelines for the management of diabetic retinopathy recommended intravitreal ranibizumab injection therapy for DME with thickening involving the centre of the macula and for clinically significant macular oedema (CSME) as defined by the ETDRS (1985) , not involving the centre of the macula, which had not responded to macular photocoagulation. This study included only eyes in the former group, that is with macula centre thickening. The injection therapy protocol prescribed 3 initial 0.5 mg intravitreal ranibizumab injections at intervals of 4 weeks followed by clinical examination including determination of BCVA and CST 4-6 weeks after the loading dose. Subsequently, a PRN phase was initiated, patients were asked to return every 4-6 weeks to get a clinical examination, and repeated one to three injections were given with the aim of treating towards BCVA and CST stability. Once stable, patients were monitored every 4-8 weeks, and if a decrease in BCVA or an increase in CST was observed in a patient with previous response to treatment, ranibizumab treatment was resumed until BCVA and CST were judged stable. Discontinuation because of a lack of apparent response was considered if BCVA remained <0.05 on consecutive visits or if there was no effect on VA and retinal thickness. Macular photocoagulation could be performed at the physician's discretion according to ETDRS guidelines with a minimum interval of 3 months. Ranibizumab injections could be switched to aflibercept or dexamethasone implant injections (Ozurdex, Allergan, CA, USA) if the condition had not improved or stabilized with active ranibizumab treatment and followup for a minimum of 6 months. Incident high-risk proliferative diabetic retinopathy, as defined by the ETDRS (1991), was treated by PRP. Incident traction detachment or traction deformation of the fovea with associated acuity reduction or persistent vitreous haemorrhage was treated by vitrectomy. Incident cataract was treated with phacoemulsification. Baseline and follow-up examinations included assessment of Snellen BCVA, slit-lamp biomicroscopy, fundus photography and optical coherence tomography (OCT) (Topcon 3D OCT, Topcon). Fluorescein angiography was made at baseline and as needed during followup. All diagnostic and therapeutic decisions were made by ophthalmologists or physicians in ophthalmology training.
Data
Clinical and demographic data were retrieved from a database and from standard patient records. Assessment visit data were paired with the closest injection visit. All OCT scans and thickness data outputs were reviewed by two experienced observers, including the first author, and manually corrected for the presence of retinal boundary line artefacts incorrectly set by built-in software segmentation. We have studied the effect of boundary line artefacts on retinal thickness and intergrader repeatability in a previous study (Hodzic-Hadzibegovic et al. 2015) .
Statistical analysis
Baseline was defined as the day the first injection was ordered. Follow-up visits were assigned to 3, 6, 9, 12, 15, 18, 24, 30, 36, 42 and 48 months within visit windows of À1.2 to +1.8 months. Transformation of Snellen acuity data to approximate ETDRS letters scores was made using this formula approximate ETDRS letter score = 85 + 50 9 log (Snellen fraction) (Gregori et al. 2010) . Baseline demographics and clinical data are presented as means (SDs) for parametric data, medians and quartiles (Q1 and Q3) for nonparametric data. Data were divided into three cohorts, 1 per year of treatment start, and the three cohorts were compared at baseline using one-way ANOVA and KruskalWallis test (Table 1) . Proportions were compared using chi-square test. A longitudinal mixed-model analysis was performed to examine changes in the outcome variables VA and OCT CST from baseline to the 4-year visit using categorical time models, correcting for repeated measurements and taking into account for values missing at random. Missing data were handled with likelihood methods, giving unbiased results. The longitudinal mixed model fitted best a nonlinear relationship with time.
The initial longitudinal mixed model presented in Table 3 was unadjusted for covariates, having only time, cohort (year of treatment start) and interaction between time and cohort in the model. If within-cohort analysis showed a significant effect of time, data were adjusted for multiple comparisons using Dunnett's test. If significant interaction between time and cohort was found, adjustment for multiple comparisons was made using Bonferroni's test. Following covariates were investigated in a mixed model for association with outcome variables (VA or CST): age, gender, diabetes type, diabetes duration, baseline haemoglobin A1c (HbA1c), DME duration, baseline CST, baseline BCVA, prior PRP, prior vitrectomy, prior laser for DME, prior steroid for DME, lens status, prior cardiovascular event, prior cerebrovascular event, hypertension and dyslipidaemia. Association between baseline VA or baseline CST and covariates was done using a regression model. Longitudinal mixed models were repeated adjusting for covariates with a p value <0.1. For the outcome VA, adjustment was made for age, baseline BCVA, baseline HbA1c, prior PRP, prior vitrectomy and prior laser for DME. For the outcome CST, adjustment was made for age, baseline CST, baseline HbA1c, prior vitrectomy, prior laser for DME and prior cerebral event. The data include 93 patients that switched to and stayed on aflibercept during follow-up, and these patients are maintained in the follow-up analysis (Fig. 1) . Fifty-one patients were switched to dexamethasone intravitreal implant during follow-up, and these patients were deleted from the time of change. Subanalysis showed similar and not significantly different results in VA and CST when these 144 patients were excluded from the data set. The statistical significance level was p < 0.05. Statistical analyses were performed using SAS software (ver.9.4; SAS Institute, Cary, NC, USA). The study was approved by the Scientific Ethics Committee of the Capital Region, Denmark (H-6-2013-016) .
Results

Baseline
The study included 566 patients [mean 63.6, standard deviation (SD) 11.6 years, females 36.6%] who started treatment with ranibizumab in 2011 (n = 114), 2012 (n = 253) and 2013 (n = 199; Table 1 ). The mean baseline VA was lowest in year 2011 and increased significantly with one line for every year of treatment initiation (p < 0.0001). Correspondingly, the baseline CST was largest in year 2011 and decreased significantly thereafter (p < 0.0001). Furthermore, the three cohorts were different in duration of DME (p = 0.0003) and prior treatment of DME with macular photocoagulation (p < 0.0001, Table 1 ). At baseline, lower VA was associated with higher age (p < 0.0001), prior PRP (p < 0.0001), prior intravitreal triamcinolone therapy (p = 0.002), prior vitrectomy (p = 0.04) and type 2 diabetes (p = 0.01). At baseline, higher CST was associated with shorter duration of diabetes (p = 0.005), lower baseline HbA1c (p = 0.04) and younger age (p = 0.04).
Follow-up
Reasons for discontinuation
At the conclusion of follow-up, 139 patients were in active ranibizumab follow-up and 88 patients were in active aflibercept follow-up. Reasons for discontinuation from ranibizumab treatment were as follows: disease stability in 179 patients, switch to other intravitreal pharmaceutical treatment in 144 patients, failure to present for follow-up in 78 patients, low VA (<0.05) in eight patients and death in 18 patients ( Fig. 1) . Discontinuation during each year of follow-up and baseline characteristics approxETDRS letters = approximate early treatment diabetic retinopathy study letters 85 letters = 20/20, BCVA = best-corrected visual acuity, CST = central subfield thickness, DME = diabetic macular oedema, HbA1c = glycosylated haemoglobin, IVT = intravitreal triamcinolone, PRP = panretinal photocoagulation, q1 = quartile 1, q3 = quartile 3, SD = standard deviation. The p-value is shown for a comparison between the three cohorts. For those with p < 0.05, a subanalysis was performed and the signatures indicate significant subcohort comparisons as; *p < 0.05 for cohort 2011 versus cohort 2012, † p < 0.05 for cohort 2012 versus cohort 2013, ‡ p < 0.05 for cohort 2011 versus cohort 2013, adjusted for multiple comparisons. divided by reason for discontinuation are summarized in Fig. 2 and Table 2 , respectively. A comparison of baseline characteristics of 93 patients who were switched from ranibizumab to aflibercept with the 422 patients who were not switched showed that switchers were more commonly female (45.2% versus 33.2%, p = 0.03), had higher baseline CST (436.1 lm versus 387.3 lm, p = 0.0004), shorter duration of DME (14.3 versus 18.6 months, p = 0.0002) and had more rarely prior laser for DME (37.6% versus 59.0%, p = 0.0002).
Treatment
The median number of follow-up visits per year for all patients was unchanged at 5 per year for all 4 years (interquartile range 3-7). For year 1, the mean number of injections for all patients was 6.1. In year 4, only 42% of the patients who were in active anti-VEGF follow-up received injections; thus, the overall mean was 1.8 injections (Table 3 ). There was no significant difference in the injection pattern between the three cohorts. A total of 4993 injections were administered in the study period. Ocular complications occurred in two patients; traumatic cataract occurred in one patient; and corneal abrasion occurred in one patient. No endophthalmitis and no major haemorrhage were registered. The median number of focal/grid laser treatment from baseline to 4 years in the 129 patients who received the treatment was one treatment, and the median number of PRP treatments in the 83 patients who received such treatment was two treatments.
Ranibizumab to aflibercept
Patients who were switched from ranibizumab to aflibercept had received ranibizumab for a mean of 1.9 years prior to the switch. Switchers received significantly more injections per year throughout the study than patients who did not switch treatment from ranibizumab, the mean number of injections being 7.1, 4.5, 4.5 and 4.7 for year 1, 2, 3 and 4 versus 5.7, 2.3, 1.8 and 1.3, respectively. The number of follow-up visits was the same, except at the fourth year where the patient who switched to aflibercept was seen more frequently.
Follow-up results
During follow-up, a major and significant improvement was seen both for VA and CST at 3 months in all cohorts (p < 0.0001, Table 4 and Fig. 3) ; thereafter, the changes were modest. The overall mean VA change from baseline to 3 months was a gain of 3.9 approx-ETDRS letters (p < 0.0001), and the overall mean CST decrease from baseline to 3 months was À97.4 lm (p < 0.0001). Overall mean VA at 3 months was not significantly different from mean VA at 12, 24, 36 and 48 months, respectively, (p > 0.05). For the 2011 cohort, a significant decrease in mean CST was found from 3 to 48 months (p = 0.0008).
Comparable gains in VA were seen for all three cohorts in the VA model, despite a lower baseline VA in the 2011 cohort (p = 0.78 for the interaction; Table 4 and Fig. 3A) . The lower VA in the 2011 cohort was most marked when compared to the 2013 cohort, where all time-points were significantly different by approximately eight letters (Table 4) . When adjusting for significant covariates (i.e. age and baseline VA), the same result was found.
There was a significant difference in the relative decrease in CST over time between the three cohorts in the thickness model (p < 0.0001 for the interaction; Table 4 and Fig. 3B ). Decrease in CST from baseline to 36 months visit was significantly larger in cohort 2011 compared to cohort 2013 and larger at 24 and 48 months in cohort 2011 compared to cohort 2012. Because of this greater decrease in CST in cohort 2011, there are no differences in mean CST values at any follow-up visit between the cohorts (Table 4) . When adjusting for significant covariates (i.e. age and baseline CST), there were no differences in the relative decrease in CST over time between the three cohorts.
Nonswitchers (n = 422) compared to patients who switched from ranibizumab to aflibercept (n = 93) showed no statistically detectable difference between ranibizumab and aflibercept treatments on VA (p = 0. Of 179 patients in which follow-up was discontinued because of disease stability, status of VA and CST at the conclusion of follow-up was found for 33 patients at Steno Diabetes Center Retinopathy Screening Service. At the screening service, VA for these 33 patients was 68.6 letters compared with 66.9 letters at baseline (p = 0.26) and 73.6 letters at the last visit (p = 0.0027). Corresponding values in CST were 267.9 lm at the screening service compared with 357.6 lm at baseline (p < 0.0001) and 275.5 lm at the last visit (p = 0.56).
Risk factors
A multivariate mixed model including all time-points, baseline demographics, systemic, ocular and OCT variables = quartile 1, q3 = quartile 3, Type 2 DM = type 2 diabetes mellitus. Percentages are based on the total number of patients included. The p-value is shown for a comparison between the seven groups. For those with p < 0.05, a subanalysis was performed and the signature *indicates significant comparison between the group of patients that were in active ranibizumab follow-up and each of the six groups that discontinued treatment adjusted for multiple comparisons.
was used to assess associations of the outcomes VA and CST (Table 5) . Visual acuity increase was associated with younger age, lower baseline VA, lower baseline HbA1c, none prior PRP and none prior vitrectomy. Central subfield thickness decrease was associated with younger age, higher baseline CST, lower baseline HbA1c, prior laser for DME and none prior vitrectomy.
The effect of baseline visual acuity
Patients with a high VA showed a smaller improvement compared to patients with lower VA (Fig. 4A ), compatible with a ceiling effect; that is, a large gain is not possible with high baseline acuity. Analysed by baseline VA group, the group of lowest VA (i.e. <58 letters) increased significantly with a mean of 8.3 letters (p < 0.0001) from baseline to 3 months and was maintained stable thereafter. Patients in the second lowest VA group (i.e. ≥58 letters and <69) had an increase in 5.9 letters (p < 0.0001) from baseline to 3 months, and then a decrease in VA towards their baseline value at 30-36 months (p = 0.01). In the second highest VA group (i.e. ≥69 and <77), the gain was 2.5 letters (p < 0.002) from baseline to 3 months and was stable thereafter. In contrast for patients with high baseline VA (i.e. ≥77 letters), the increase was a nonsignificant mean of 0.4 letters from baseline to 3 months and then a decrease in four letters compared to baseline (p = 0.08) at 18 and 24 months. The relative treatment effect on CST varied significantly according to initial VA (p < 0.0001; Fig. 4B ). There was a significant decrease in CST in all VA groups from baseline to 3 months, from lowest to highest VA group, respectively, À111.9, À132.6, À70.3 and À64.4 lm, thus including a marked decrease in CST of À64.4 lm (p < 0.0001) even in patients with high VA (≥77 letters).
Correlation between visual acuity and CST
In Fig. 5 , OCT CST is plotted against VA at baseline and at the last visit. Patients are divided into four subgroups of combined VA and CST. The distribution of CST plotted against VA shows a marked shift from baseline to the final visit in that it shifted markedly towards lower CST and towards higher VA. The correlation coefficient at baseline was 0.42 (p < 0.0001) and at the final visit 0.25 (p < 0.0001). At baseline, the number of patients with high CST and low VA was 151, decreasing to 50 at the final visit. In contrast, the number of patients with high VA and low CST increased from 221 to 351.
Nonimprovers
Failure to achieve a reduction in CST of at least 10% compared to baseline during the first year of treatment with ranibizumab was seen in 79 of 566 (14.0%) patients. The 79 nonimprovers were evenly distributed between the different baseline acuity groups, 21.5% (<58 letters), 24.1% (≥58 to <69 letters), 30.4% (≥69 to <77 letters) and 24.0% (≥77 letters). At baseline, nonimprovers were more frequently type I diabetics (p = 0.03), had longer diabetes duration (p = 0.0008), had lower CST (p < 0.0001), more frequently had prior PRP (p = 0.03), more frequently had prior vitrectomy (p < 0.0001) and were more often pseudophakic (p = 0.01) compared to the rest of the study population. Despite the lack of improvement in CST, a graphic presentation of the course of VA in nonimprovers showed increase in VA that was comparable to improvers during the first 12 months (Fig. 6) and a mixed-model analysis comparing VA outcome in the first year in nonimprovers and the rest of the study population showed no statistically significant difference between the two groups (p = 0.10). After 12 months, 38 patients, or nearly half of the nonimprovers, were discontinued (25 patients) or changed treatment to dexamethasone intravitreal implant (13 patients). Of 41 patients who continued treatment after 12 months, 14 were switched in treatment to aflibercept and 27 continued on ranibizumab.
The effect of number of anti-VEGF injections
Number of injections is a significant factor for the visual prognosis and for every extra injection there is an increase in 1.01 letters (p < 0.0001) adjusted for significant covariates (i.e. age and baseline VA).
Cataract surgeries
At baseline, 130 patients (23.0%) were pseudophakic and 436 patients (77.0%) were phakic. During the study, on average at 24 months (range 3-42 months), 56 patients (9.9%) underwent cataract surgery. In a mixed-model analysis, we found that pseudophakic patients and phakic patients had the same development in VA during anti-VEGF therapy (p = 0.59), irrespective of time-point for cataract surgery. In addition, we adjusted for covariates baseline VA, age, duration of diabetes, baseline HbA1c and prior laser treatment, and the same result was found (p = 0.31). The 56 patients who underwent cataract surgery during the study, had at baseline 30.9% of patients in low BCVA and high CST group and 36.4% of patients in high BCVA and low CST group (i.e. in total 67.3% of patients were in the nonparadoxical groups). This is similar to 65.8% in patients with no cataract surgery during the study and 64.8% in patients' pseudophakic at baseline.
Discussion
The study included 566 patients with diabetes who initiated treatment in their first eye with ranibizumab for three time cohorts with initiation in 2011, 2012 and 2013 following Danish national guidelines. Focal or grid laser was administered in 129 patients during the study. Overall, a statistically significant improvement of approximately 3.9 ETDRS letters was found at 3 months for all cohorts. Visual acuity (VA) outcomes gained at 3 months were maintained stable at year 1, 2, 3 and 4 for all cohorts. Mean number of injections per year was 6.1, 3.0, 2.6 and 1.8, respectively, for year 1, 2, 3 and 4. For CST, the decrease was also statistically significant for all three cohorts at 3 months. Central subfield thickness (CST) outcomes at 3 months were sustained at year 1, 2, 3 and 4, except for the 2011 cohort with significantly lower CST at year 4 compared to at 3 months. Baseline VA had a pronounced effect on visual outcome. To compare the VA benefit in our study with prior studies, we analysed the group of patients with baseline VA below 77 ETDRS letters, as most prospective studies have an upper limit on baseline VA (Nguyen et al. 2009 (Nguyen et al. , 2012 Clinical Diabetic Retinopathy Research Network et al. 2010; Massin et al. 2010; Lang et al. 2013; Ishibashi et al. 2015; Pearce et al. 2015; Wells et al. 2015; Prunte et al. 2016 ). For the group of patients with VA below 77 ETDRS Table 4 . Visual acuity and central subfield thickness from baseline up to 4 years in all patients and divided by year of treatment start. (96) 404 (71) 332 (59) 213 (38) 79 ( 108 (95) 86 (75) 72 (63) 55 (48) 51 (45 (98) 181 (72) 150 (59) 110 (44) 28 ( (94) 137 (69) 110 (55) 48 ( DBCVA = change in best-corrected visual acuity from baseline, a negative number indicates a less favourable outcome for a numerical increase in the covariate, DCST = change in central subfield thickness from baseline, a positive number indicates a less favourable outcome for a numerical increase in the covariate, CST = central subfield thickness, DME = diabetic macular oedema, HbA1c = glycosylated haemoglobin, PRP = panretinal photocoagulation, VA = visual acuity. letters, the mean improvement in VA from baseline was +5.3, +5.1, +4.5, +3.7 and +4.2 ETDRS letters, respectively, at 3, 12, 24, 36 and 48 months. Our results are lower than the 1-year results in the DRCR.net Protocol I study (+9 letters in ranibizumab + prompt/ deferred laser arms) (Clinical Diabetic Retinopathy Research Network et al. 2010) , Protocol T study (+11.2 letters in ranibizumab arm) (Wells et al. 2015) and RESOLVE study (+10.3 letters) (Massin et al. 2010 ) and lower than the 2-and 3-year results in RISE & RIDE study (Nguyen et al. 2012; Brown et al. 2013) . These results were achieved with a median number of injections in the first year, respectively, 9, 10, 10, 12 and 12. Our patients received 6.1 injections the first year (maximum possible injections, 13), thereafter decreasing to a mean of 1.8 in year 4. Protocol I found that the VA gain seen at 1 year was sustained up to 5 years after treatment initiation with a reduced number of injections.
The superior results achieved with Protocol I could be caused by strict rules for injections ending up in more injections and exclusion of patients; thus, the proportion of patients with prior PRP was lower (i.e. less severe DR levels) and baseline HbA1c was lower compared to our study population. In our analysis, we found that none prior PRP and lower baseline HbA1c were independently associated with an increase in VA. Our results are comparable to the 1-year results of the following studies, RESTORE study (+6.8 and 6.4 letters in the ranibizumab and ranibizumab+laser arms, respectively) (Mitchell et al. 2011 ), RELIGHT study (+4.8 letters) (Pearce et al. 2015) , REVEAL study (+5.9 and 5.7 letters in the ranibizumab and ranibizumab+laser arms, respectively) (Ishibashi et al. 2015) and RETAIN study (+6.2 letters) (Prunte et al. 2016) . In these four studies, patients received a median of seven injections the first year. In the RESTORE study, the VA gained the first year in the ranibizumab AE laser groups was maintained at 3 years with a declining number of injections. Our results are more comparable to these four studies, Fig. 6 . Mean best-corrected visual acuity in number of approximate early treatment diabetic retinopathy study (approxETDRS) letters (A) and mean central subfield thickness in lm (B) in nonimprovers as a function of time after initiation of intravitreal vascular endothelial growth factor (VEGF)-inhibitor treatment in anti-VEGF-na€ ıve eyes by baseline visual acuity quartile [<58 (blue), ≥58 to <69 (red), ≥69 to <77 (green), ≥77 letters (brown)]. Fig. 5 . Central subfield thickness in relation to BCVA before (A) and after treatment of diabetic macular oedema (final visit) (B) divided by visual acuity and central subfield thickness group status at baseline [Group 1 BCVA <69 and CST ≥400 (blue), Group 2 BCVA <69 and CST <400 (red), Group 3 BCVA ≥69 and CST ≥400 (brown) and Group 4 BCVA ≥69 and CST <400 (green)]. BCVA = best-corrected visual acuity, CST = central subfield thickness, approxETDRS = approximate early treatment diabetic retinopathy study.
possibly because these four studies have less strict retreatment criteria and a higher frequency of patients with good baseline VA than the four studies mentioned above. In our analysis, we found that the number of anti-VEGF injections does affect positively the visual prognosis. Adjusted for significant covariates, we found that one extra anti-VEGF injection improves VA by 1.01 ETDRS letter. The Danish national guidelines are individualizing the anti-VEGF treatment of DME, in an attempt to minimize the injection burden in a relatively young patient population in a risk of disease recurrence. This results in a potential loss of five letters compared to the studies with a higher injection frequency rate during the first year. To our knowledge, this is the largest and most comprehensive data from a single centre on the long-term results of realworld clinical experience of DME treated with ranibizumab. There are three retrospective studies with a maximum of 18 months of follow-up and one study with a 4-year follow-up newly published (Brynskov et al. 2013; Menchini et al. 2015; Patrao et al. 2016 ). In the Swedish study, 80 patients with initial BCVA of no greater than 73 letters and no prior ocular surgery received a mean of 4.7, 1.4, 0.7 and 0.9 injections per year from baseline to year 4 and had an increase in BCVA of 6.6 letters, which was sustained during the 4-year follow-up (Epstein & Amren 2017) . In the Morfields eye study, 164 patients received a mean of 7.2 injections over a follow-up up to 12 months and had an increase in BCVA of 6.6 letters and a decrease in CST of À134 lm. In the Roskilde study in Denmark, 62 patients with a follow-up up to 15 months had gained five letters in BCVA with a mean of five injections and decreased 98 lm in CST. In the PRIDE study in Italy, 515 patients had 1.0 decimal score visual gain with a median of four injections.
In our study, 146 patients were in the highest baseline VA group (≥77 letters). For this particular group, no nominal BCVA gain was achieved (+0.4 letters) indicating a ceiling effect, but the patients experienced a positive effect of the treatment, with a clinically significant decrease in CST of À64.4 lm at 3 months which was sustained up to 4 years. As no control group was included we cannot compare to the effect of photocoagulation. In the early studies where photocoagulation alone was used for treatment of patients with DME, patients with good initial VA were also included in these studies, but an improvement in VA of six or more letters was uncommon in this group of patients (1985) . Although photocoagulation was effective in reducing the risk of moderate vision loss (≥15 letters loss) by 50% compared to the natural history, a substantial proportion of treated eyes remained unresponsive.
A modest correlation between VA and CST was found in our study, at baseline the correlation coefficient was 0.42 (p < 0.0001) and at the final visit 0.27 (p < 0.0001). These results show that CST alone is not a good surrogate for VA. Several variables affect VA, that is status of the photoreceptors (Chung et al. 2012 ), thickness of ganglion cell-inner plexiform layer (Bonnin et al. 2015) and disorganization of the inner nuclear layers (Sun et al. 2014 ) and a low VA may reflect such changes also if the retinal thickness is normalized. Therefore, the degree of macular thickness may not only represent the degree of the breakdown of the bloodretinal barrier (BRB). Inflammation, neuronal degeneration, macular ischaemia and vitreoretinal traction can be some of the other components of DME.
We included both patients treated with ranibizumab and patients (~16%) that were switched approximately at 2 years from ranibizumab to aflibercept. There were no difference in baseline VA between the two groups, but the patients that were changed to aflibercept had higher CST, shorter duration of DME and received less prior laser for DME. Aflibercept for DME was approved by the European Commission on 6 August 2014; therefore, the proportion of patients that were switched to aflibercept were different between the three cohorts, respectively, nine (7.9%), 38 (15.0%) and 46 (23.1%) patients from 2011, 2012 and 2013 cohorts (p = 0.002) and patients that were changed needed more ranibizumab injections during the first year. Thus, these patients differ in some aspects from patients that remained on ranibizumab. However, the possible effect of the treatment shift from ranibizumab to aflibercept was not statistically significant for the outcome in the VA model and in the CST model and in a sensitivity analysis.
Patients who were discontinued because of disease stability at the time of discontinuation had a mean follow-up of <2 years and a mean of 5.1 injections in year one and 1.4 injections in year two. They demonstrated a significant improvement in VA and CST at the time of discontinuation. For one-fifth of these patients, status at the conclusion of follow-up was found at a DR screening service, stability in CST and a decrease in VA of five approximate ETDRS letters compared to the time of discontinuation. This difference in BCVA can be explained by the difference in VA assessment between the DR screening service and the medical retina service where VA is measured, respectively, post-and predilatation (Sun et al. 2009 ).
We also analysed the pattern of nonimprovement, defined as a <10% decrease in CST during the first year of treatment. The nonimprovers group (~14%) was approximately evenly distributed between the VA groups, suggesting that the reason for nonimprove is multifactorial.
Overall conclusions were not affected by lens status. Increase in VA was the same regardless of lens status, proposing that the VA results were not confounded by progression of cataract. The time-point that cataract surgery was performed was wide, from 3 to 42 months after baseline, proposing that cataract surgeries were not deferred, but offered when necessary. Furthermore, equal proportions of patients were switched to aflibercept. More patients defined as nonimprovers were pseudophakic at baseline (p = 0.01); however, equal proportions underwent cataract surgery. The modest correlation between VA and CST found in this study cannot be explained by cataract or cataract surgery.
In summary, in this large, singlecentre study on the effect of anti-VEGF treatment following Danish national guidelines, we found an overall gain in VA of 3.5 ETDRS letters after 6.1 injections the first year which was sustained at year 2, 3 and 4 with a declining number of injections. For patients with baseline VA worse than 77 ETDRS letters, the gain was 5.1 ETDRS letters at year 1. The visual outcome is below the clinical studies, but studied on a wider population and achieved with fewer injections. The marked improvement was maintained up to 4 years with few additional injections.
